A 42-year-old woman with a 10-year history of asthma and chronic rhinosinusitis presents with recurrent bilateral nasal polyps. She underwent FESS with polyp removal 2 years ago but has had two recurrences since. Endoscopy now shows bilateral polyps with eosinophilic inflammation on biopsy. She is already on high-dose intranasal fluticasone (200 µg BD) and oral montelukast. What is the most appropriate next step in management?

Explanation

## Clinical Context: Recurrent Eosinophilic Nasal Polyposis **Key Point:** Recurrent nasal polyps with eosinophilic inflammation despite maximal intranasal and systemic medical therapy indicate eosinophilic nasal polyposis (ENP) — a phenotype requiring biologic therapy. ## Diagnostic Features of This Case | Feature | Significance | |---------|-------------| | **Bilateral polyps** | Suggests systemic inflammatory process, not localized disease | | **Recurrent after FESS** | High recurrence rate (>30% at 2 years) indicates aggressive disease | | **Eosinophilic inflammation on biopsy** | Hallmark of eosinophilic nasal polyposis (ENP) | | **Asthma + chronic rhinosinusitis** | Classic ENP phenotype; often associated with aspirin sensitivity | | **Failed maximal medical therapy** | High-dose intranasal steroids + oral montelukast insufficient | ## Management Algorithm for Recurrent Polyps ```mermaid flowchart TD A[Recurrent nasal polyps post-FESS]:::outcome --> B{Biopsy findings?}:::decision B -->|Eosinophilic inflammation| C[Eosinophilic nasal polyposis]:::outcome B -->|Non-eosinophilic| D[Standard recurrent polyp pathway]:::outcome C --> E{On maximal medical therapy?}:::decision E -->|No| F[Optimize intranasal + oral steroids<br/>+ leukotriene antagonist]:::action E -->|Yes| G[Consider biologic therapy]:::action G --> H{Eligible for dupilumab?}:::decision H -->|Yes| I[Dupilumab 400-600 mg loading<br/>then 300 mg SC Q2W]:::action H -->|No| J[Consider repeat FESS<br/>if severe obstruction]:::action I --> K[Reassess at 4-6 months]:::outcome ``` ## Why Dupilumab is the Best Next Step **High-Yield:** Dupilumab (anti-IL-4 receptor monoclonal antibody) is now the standard biologic therapy for eosinophilic nasal polyposis refractory to medical management. ### Mechanism of Action - Blocks IL-4 receptor α subunit, inhibiting both IL-4 and IL-13 signaling - Reduces Th2-mediated eosinophilic inflammation - Decreases polyp size and recurrence ### Evidence in ENP - **LIBERTY NP trials** demonstrated significant reduction in polyp burden and nasal obstruction scores - **FDA approval (2019)** for moderate-to-severe chronic rhinosinusitis with nasal polyps - **Recurrence prevention:** Reduces polyp recurrence by ~60% compared to placebo ### Dosing - **Loading:** 400 mg (2 × 200 mg) or 600 mg (3 × 200 mg) SC - **Maintenance:** 300 mg SC every 2 weeks - **Duration:** Typically 6–12 months; reassess at 4–6 months **Clinical Pearl:** Dupilumab is particularly effective in patients with asthma + CRS-NP, as it addresses both conditions. This patient's asthma makes her an ideal candidate. ## Why Other Options Are Suboptimal **Repeat FESS:** While surgery may provide temporary relief, it does not address the underlying eosinophilic inflammation and has a high recurrence rate (>50% within 2 years in ENP). Surgery alone is insufficient in this phenotype. **Oral corticosteroids:** Systemic steroids carry significant long-term risks (osteoporosis, infection, metabolic effects) and are not indicated as monotherapy. They may be used as a bridge to biologic therapy but are not definitive. **Allergen-specific immunotherapy:** While allergy may contribute, the eosinophilic inflammation is primarily Th2-driven and not solely allergic. Immunotherapy alone will not address the polyp burden. [cite:Bachert C, et al. J Allergy Clin Immunol. 2019;144(6):1542–1552; Wechsler ME, et al. N Engl J Med. 2021;384(18):1695–1706]